• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CEO & Co-Founder Perez Daniel Antonio converted options into 166,665 shares and sold $7,730,617 worth of shares (166,665 units at $46.38) (SEC Form 4)

    1/6/26 4:58:12 PM ET
    $HNGE
    EDP Services
    Technology
    Get the next $HNGE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Perez Daniel Antonio

    (Last) (First) (Middle)
    C/O HINGE HEALTH, INC.
    455 MARKET STREET, SUITE 700

    (Street)
    SAN FRANCISCO CA 94015

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Hinge Health, Inc. [ HNGE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    CEO & Co-Founder
    3. Date of Earliest Transaction (Month/Day/Year)
    01/05/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 01/05/2026 C 166,665 A $0 166,665 D
    Class A Common Stock 01/05/2026 S(1) 122,368 D $46.2458(2) 44,297 D
    Class A Common Stock 01/05/2026 S(1) 44,297 D $46.7664(3) 0 D
    Class A Common Stock 35,470 I By Spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Common Stock (4) 01/05/2026 C 166,665 (4) (4) Class A Common Stock 166,665 $0 14,376,762 D
    Class B Common Stock (4) (4) (4) Class A Common Stock 515,705 515,705 I By Spouse
    Explanation of Responses:
    1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2025.
    2. Represents the weighted average sale price. The lowest price at which shares were sold was $45.47 and the highest price at which shares were sold was $46.46. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
    3. Represents the weighted average sale price. The lowest price at which shares were sold was $46.47 and the highest price at which shares were sold was $46.97. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
    4. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
    /s/ James Budge, Attorney-in-Fact 01/06/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HNGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNGE

    DatePrice TargetRatingAnalyst
    1/9/2026$68.00Overweight
    Wells Fargo
    9/5/2025$56.00Neutral
    Robert W. Baird
    7/14/2025$58.00Mkt Outperform
    Citizens JMP
    6/16/2025Outperform
    William Blair
    6/16/2025$48.00Buy
    Truist
    6/16/2025$48.00Buy
    Stifel
    6/16/2025$45.00Outperform
    Raymond James
    6/16/2025$41.00Overweight
    Piper Sandler
    More analyst ratings

    $HNGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Hinge Health with a new price target

    Wells Fargo initiated coverage of Hinge Health with a rating of Overweight and set a new price target of $68.00

    1/9/26 9:05:22 AM ET
    $HNGE
    EDP Services
    Technology

    Robert W. Baird initiated coverage on Hinge Health with a new price target

    Robert W. Baird initiated coverage of Hinge Health with a rating of Neutral and set a new price target of $56.00

    9/5/25 7:59:54 AM ET
    $HNGE
    EDP Services
    Technology

    Citizens JMP initiated coverage on Hinge Health with a new price target

    Citizens JMP initiated coverage of Hinge Health with a rating of Mkt Outperform and set a new price target of $58.00

    7/14/25 8:51:47 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    SEC Filings

    View All

    Hinge Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Hinge Health, Inc. (0001673743) (Filer)

    2/10/26 4:07:20 PM ET
    $HNGE
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Hinge Health Inc.

    SCHEDULE 13G/A - Hinge Health, Inc. (0001673743) (Subject)

    2/2/26 4:30:46 PM ET
    $HNGE
    EDP Services
    Technology

    SEC Form SCHEDULE 13G filed by Hinge Health Inc.

    SCHEDULE 13G - Hinge Health, Inc. (0001673743) (Subject)

    1/30/26 2:18:51 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Pursley James covered exercise/tax liability with 1,429 shares, decreasing direct ownership by 0.19% to 767,231 units (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/3/26 8:45:27 PM ET
    $HNGE
    EDP Services
    Technology

    Chief Financial Officer Budge James covered exercise/tax liability with 3,036 shares, decreasing direct ownership by 0.69% to 434,895 units (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    2/3/26 8:44:14 PM ET
    $HNGE
    EDP Services
    Technology

    CEO & Co-Founder Perez Daniel Antonio converted options into 166,665 shares and sold $7,730,617 worth of shares (166,665 units at $46.38) (SEC Form 4)

    4 - Hinge Health, Inc. (0001673743) (Issuer)

    1/6/26 4:58:12 PM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hinge Health reports fourth quarter and full year 2025 financial results

    Hinge Health, Inc. (NYSE:HNGE) today announced record financial results for the quarter and year ended December 31, 2025. "We closed out the year with an exceptional quarter and a strong selling season, driving our highest win rates to date and greatest number of eligible lives added in any year," said Daniel Perez, Co-Founder and CEO, Hinge Health. "Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence in our ability to continue automating care delivery, sustain our position as a leader in digital musculoskeletal care, and drive attractive growth and increased margins in 2026." Fourth Quarter 2025 Financial Highlights: Revenue incre

    2/10/26 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health's 2026 State of Musculoskeletal Care Report reveals stark gaps in traditional care

    Today, Hinge Health (NYSE:HNGE) released its sixth annual State of Musculoskeletal (MSK) Care Report, revealing how today's fragmented healthcare system leaves many people unsure how to pursue treatment for MSK pain. Hinge Health surveyed 1,000 people living with MSK pain alongside 295 healthcare providers to understand the systemic challenges and opportunities for industry-wide improvements. The dual-perspective survey – along with real patient and provider stories – maps a clear path to more effective, unified care. "While Hinge Health's digital physical therapy program has dramatically increased access, MSK care still feels like a maze for too many people," said Dr. Jeffrey Krauss, MD,

    1/15/26 11:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    $HNGE
    Financials

    Live finance-specific insights

    View All

    Hinge Health to announce fourth quarter and full year 2025 financial results on February 10, 2026

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the fourth quarter and full year 2025 after the U.S. financial markets close on Tuesday, February 10, 2026. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, st

    1/14/26 9:00:00 AM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health to announce third quarter 2025 financial results on November 4, 2025

    Hinge Health, Inc. (NYSE:HNGE) announced today that it will report its financial results for the quarter ended September 30, 2025, after the U.S. markets close on Tuesday, November 4, 2025. Hinge Health will also host an earnings conference call to discuss its results and guidance at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) the same day. The live audio webcast of the earnings conference call will be available on the Hinge Health Investor Relations website at ir.hingehealth.com. A replay of the webcast will be available on the same website shortly after its completion. About Hinge Health Hinge Health is focused on scaling and automating the delivery of health care, starting with

    10/1/25 5:00:00 PM ET
    $HNGE
    EDP Services
    Technology

    Hinge Health Reports Second Quarter 2025 Financial Results

    Hinge Health, Inc. (NYSE:HNGE) today announced financial results for the second quarter ended June 30, 2025. "In Q2 we delivered year-over-year revenue growth of 55% and a strong free cash flow margin, underlining the market's embrace of our AI-powered platform," said Daniel Perez, Co-Founder and CEO, Hinge Health. "The journey of automating healthcare delivery will be challenging, but we're excited about our momentum and are moving with haste to capture this opportunity." Second Quarter 2025 Financial Highlights: Revenue increased 55% year-over-year to $139.1 million compared to revenue of $89.8 million in Q2 2024. GAAP gross margin was 70% compared to 74% in Q2 2024. Non-GAAP gr

    8/5/25 4:05:00 PM ET
    $HNGE
    EDP Services
    Technology